Merck
HomeWebinarsWhat Does the Future Hold for Biomarker R&D?

What Does the Future Hold for Biomarker R&D?



WEBINAR

Biomarkers are particularly important in the pharmaceutical industry to evaluate the safety and effectiveness of a drug. Biomarkers could help decrease the costs of drug development by enabling early proof-of-concept studies for novel therapeutic targets, thus reducing costly drug attrition rates.

However, challenges remain in validating biomarkers for different areas of study utilizing many different technologies. There are many opinions and ideas for how biomarker validation may develop and evolve in the future.

In this panel discussion, we hear from key experts in the field about their research and expertise, how they overcome key challenges associated with the technologies they work with, and what they envision for the future of biomarker research and validation.

For Research Use Only. Not For Use In Diagnostic Procedures.

Request Info on SMC® Assays

Speakers

Anitaben Tailor, Ph.D.

Anitaben Tailor, Ph.D.

Merck

Biology Technical Marketing

Anitaben Tailor brings over 10 years of immunoassay platform experience in the biopharmaceutical industry. Anita earned her Master’s in Pharmacology at Kings College, London and then went on to do her Ph.D. in Biochemical Immunopharmacology at the University of London, UK. She was a Post-Doctoral Fellow in physiology and pharmacology at LSU Health Sciences, followed by faculty positions at Johns Hopkins and NIH. In 2009, Anita moved into industry as a Field Application Scientist for Meso Scale Diagnostics and Singulex® Inc. In 2016, Anita was appointed the global role of SMC® Technology and Application Lead within the Life Science Division at our company, where she led multiple teams globally on the utility of SMC® technology as a bioanalytical tool for multiple research applications within industry and academia. More recently Anita joined the global Biology Technical Marketing group, focusing on the Immunoassay portfolio within Pharma and CROs.

Dominic Warrino, Ph.D.

Dominic Warrino, Ph.D.

KCAS

Senior Scientific Advisor

Dominic Warrino is the Senior Scientific Advisor at KCAS (KS, USA). Dominic joined the company in 2013 and brought with him expertise in a full range of bioanalytical techniques including ECL, ELISA, RIA, flow cytometry, ELISpot, cell-based assays, and Luminex® assays. He also serves in business development as a technical consultant. Dominic has 20 years of experience developing and validating immunological assays for biotechnology and pharmaceutical companies. He most recently spent the past several years in the Biopharma Services department at Viracor-IBT (MO, USA) (formally IBT).

Hanna Ritzén

Hanna Ritzén

Mercodia AB

Managing Director Research and Development

Hanna Ritzén is currently Managing Director of Research and Development at Mercodia AB (Uppsala, Sweden), a Swedish biotech company that specializes in the development and production of ELISA assays as well as bioanalytical services. Hanna is responsible for the development of commercial IVD and RUO ELISA kits as well as the method development, validation, and sample analysis in bioanalytical services. Hanna started with Mercodia in 2002 as a Product Development Scientist and has been involved in the CAPA process and life cycle management of ELISAs as well as the standardization and harmonization of methods.

Ginger Milne, Ph.D.

Ginger Milne, Ph.D.

Vanderbilt University

Research Associate Professor of Medicine and Pharmacology; Director, Eicosanoid and Neurochemistry Labs

Ginger Milne is a chemist working as a Research Associate Professor of Medicine and Pharmacology in the Medical Center at Vanderbilt University. Based within the School of Medicine, she has directed the Eicosanoid Core Laboratory for almost 14 years where she collaborates with and oversees the provision of analytical services to researchers both within Vanderbilt University and across the globe. Using Waters Corporation equipment, the lab performs 16 validated, highly precise and sensitive mass spectrometry assays, several of which were developed by Milne’s team. Milne and her team are focused on measuring prostaglandin metabolites in urine as biomarkers of cancer.

Tom Angel

Tom Angel

GlaxoSmithKline

Senior Scientific Investigator – Exploratory Biomarker Group

Tom Angel is a biochemist with a keen interest in the application of high-resolution mass spectrometry to address a wide range of unmet needs and longstanding challenges in biological sciences. Tom has more than 15 years of experience in biomedical research, expertise in mass spectrometry-based protein analysis and proteomics. In his current position as Senior Scientific Adviser at GSK (Brentford, UK), Tom is charged with advancing the application of stable isotope metabolic labeling supporting portfolio development by delivering protein turnover assays (kinetic biomarker assays) for bespoke targets.